Prevalence of atopic eczema and related symptoms in Brazilian schoolchildren: results from the International Study of Asthma and Allergies in Childhood (ISAAC) phase 3.

BACKGROUND: International comparisons of the prevalence of atopic eczema and related symptoms are scarce. The standardized protocol of the International Study of Asthma and Allergies in Childhood (ISAAC) facilitates investigation of prevalence all over the world. OBJECTIVE: To apply the ISAAC written questionnaire to evaluate the prevalence of atopic eczema and related symptoms among 6-7 year-old children and 13-14 year-old adolescents living in 20 Brazilian cities. METHODS: The ISAAC written questionnaire was filled in by 23,422 children aged 6-7 years and 58,144 adolescents aged 13-14 years living in 2 population centers in the north, 8 in the northeast, 1 in the midwest, 5 in the southeast, and 5 in the south. RESULTS: The prevalence of flexural eczema (itchy rash ever in characteristic places in the last 12 months) ranged from 5.3% to 13.0% for children and was lower among the adolescents (range, 3.4%-7.9%). Among children, the highest rates were observed in population centers in the northeast, mainly along the coast. Among adolescents the highest rates were observed in the north and northeast, mainly in Natal, Aracaju, and Vitória da Conquista. The northeastern countryside had higher prevalence rates of severe eczema (kept awake at night by this itchy rash in the last 12 months) in comparison to northeastern coastal centers. There was a significant correlation between the prevalence of flexural eczema and severe eczema for both age groups, separately (6-7 year-olds, prho= 0.756, P<.004; 13-14 year-olds, rho=0.874, P<.0001) or grouped (6-7 plus 13-14 years-olds, rho=0.696, P<.0001). CONCLUSION: The prevalence of eczema and related symptoms is variable in Brazil, where the highest prevalence is found in the north and northeast; on the other hand, a higher prevalence of severe eczema was observed in Brazilian centers in the south.

Avaliação espirométrica de crianças e adolescentes asmáticos acompanhados em ambulatório especializado / Spirometric evaluation of asthmatic children and adolescents followed in specialized out-patient clinic

Objetivo: descrever características espirométricas de crianças e adolescentes asmáticos acompanhados em ambulatório especializado. Métodos: cem asmáticos maiores de seis anos foram aleatoriamente convidados para o estudo. Sete recusaram-se a participar. Testes de função pulmonar (FP) foram realizados pela manhã (espirômetro Vitalograph®), quando os pacientes estavam livres de infecções respiratórias há pelo menos duas semanas e após suspensão de broncodilatadores de curta elonga ação. Foram obtidas curvas de fluxo-volume antes e 15 minutos após inalação de 400g de salbutamol. Doze pacientes não foram capazes de realizar curvas reprodutíveis. Resultados: a mediana de idade, foi 11,5 anos. Dezenove pacientes apresentavam asma intermitente (AI), 24 asma persistente leve (APL), 22 asma persistente moderada (APM) e 16 asma persistente grave (APG). As medianas dos valores basais de FP para AI, APL, APM e APG foram respectivamente: capacidadevital forçada (CVF): 96 per cent, 88 per cent, 84 per cent e 90 per cent; volume expiratório forçado no primeiro segundo (VEF1): 84 per cent, 82 per cent, 73 per cent e 65 per cent; fluxo expiratório forçado entre 25 per cent e 75 per cent da CVF (FEF25-75 per cent): 78 per cent, 66 per cent, 60 per cent e 43 per cent. Houve aumento significante nos valores de FP após salbutamol para todos os parâmetros avaliados. Não houve correlação entre a gravidade da asma e o incremento de FP após salbutamol. O FEF25-75 per cent foi o parâmetro que melhor discriminou a gravidade da asma e que indicou alterações funcionais em maior número de casos. Nãohouve correlação entre o tempo de doença e os valores de FP. Conclusões: a espirometria é útil na avaliação de crianças e adolescentes asmáticos. O FEF25-75 per cent é o parâmetro mais sensível para a avaliação da gravidade da doença.

[Laboratorial tests in pulmonary diseases] / O laboratório nas doenças pulmonares.

OBJECTIVE: The authors present a review about the diagnosis of pulmonary diseases, with special emphasis on laboratorial procedures. METHODS: The most important articles about laboratorial procedures were selected through Medline search. RESULTS: To diagnose pulmonary diseases we need to evaluate clinical history, laboratorial tests, several radiografic techniques, bronchoscopy, thoracentesis and lung biopsy among others. We present the main laboratorial tests which include the clinical tests and pulmonary function evaluation to diagnose these diseases. CONCLUSION: The laboratorial tests are part of pulmonary tests diagnosis. The obtained results should be associated with clinical history and the other diagnostic methods.

Reduction in the oral doses of theophylline in asthmatic children during concomitant treatment with ketotifen.

Sixteen children with moderate or severe bronchial asthma underwent a double-blind study receiving either ketotifen (K) or placebo (P) in order to verify the sparing effect of K on theophylline. The study lasted 18 weeks. Slow release theophylline was administered to all patients at a dose of 300 mg every 12 hours for the first six weeks of the study ("washout"). From the seventh week on, eight patients received K (1 mg, 2x/day) and the others P. The theophylline dose was maintained and reduced every 4 weeks to 200 mg and 100 mg. The initial clinical characteristics were identical in both groups. The serum levels of theophylline decreased below the ideal range (less than 10 mcg/ml) in groups K and P with a 100 mg dose of theophylline. However, in group K patients, fewer reported worsening of symptoms (number of days with cough and/or wheeze, altered daytime or nighttime peak expiratory flow rate and consumption of beta agonist) when compared to group P. Increased PC20 of methacholine only occurred in group K patients.

Bronchial provocation with metacholine in young children: a simplified method.

Although pointed out as a characteristic of bronchial asthma, bronchial hyperreactivity (BH) has been documented in other clinical situations such as fibrocystic disease of pancreas and chronic obstructive pulmonary disease. BH is diagnosed in 90% of asthmatic patients and in almost all of those who are symptomatic. BH can be measured by specific bronchial provocation tests (BPT) (antigens and occupational sensitizing agents) and by exercise. Since their introduction, nonspecific BPT have been extensively used as a preliminary method for the evaluation of BH and also to diagnose bronchial asthma, to establish its severity, to determine the therapeutic efficacy of drugs, and for epidemiological studies.